Blue Zone Therapeutics

Blue Zone Therapeutics is described on its official website as a new biotech company built from the research of Dr. Bréchot, whose work includes viral hepatitis (HBV/HCV), liver cancer and regeneration, and the role of a C-type lectin in resistance to insulin, diabetic neuropathy, and Alzheimer’s diseases. The company notes that Dr. Bréchot has authored 400+ articles, holds 18 patents, and contributed to founding multiple biotech companies, including Rarecells, The Healthy Aging Company, and now Blue Zone Therapeutics. [1]

Externally, Blue Zone Therapeutics is characterized as developing innovative, effective, and practical treatments aimed at age-related diseases in pets, with the goal of improving lifespan and quality of life for companion animals. An ecosystem interview further frames the rationale as an unmet need: pets experience chronic diseases similar to humans, but therapeutic options are limited; the company positions itself as bridging cutting-edge biomedical research with practical veterinary applications. [2][4]